Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silexan in mild to moderate major depressive disorder
2025-521744-37-00Phase 3Authorised
- Sponsor
- Schwabe Group
- Start
- Nov 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Silexan with Placebo (2 arms). Primary endpoint: Change in MADRS total score. Planned start Nov 2025; status: authorised.
02
Drugs
Silexan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-521744-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521744-37-00.